Industry News

Will We Ever Be Able to Rein in Healthcare Spending?

Richard Foster takes his experience of working with the National Health Expenditures (NHE) team in the CMS Office of the Actuary to talk about healthcare spending in the United States, how we've come to this point, and where we're likely headed. Read more here. (Source: Richard Foster, HealthAffairs[...]

FDA Discusses Broader Use Of RWE With Industry Leaders

Current legislative authority for the Prescription Drug User Fee Act (PDUFA) is set to expire in September 2017, so industry groups BIO and PhRMA have already  begun meeting with officials from the US Food and Drug Administration (FDA). Take a look at what has been discussed here. (Source: Zachary [...]

How Could VBP Help Lower High Rx Costs?

Several speakers at a recent forum on drug pricing talked about the use of Value-Based reimbursement as a step in the right direction against rising drug prices. Are value based payments really a viable option? Read more here. (Source: Joyce Frieden, Medpage Today, 11/23/15)[...]

Who Really Deserves Credit for Discovery Of Statistical Regression

Thanks Evidence Soup for posting this great article in this week's 5 links on evidence-based decision making. Read about how Gauss discovered statistical regression,   but didn't share it. Later, Legendre published the method, sparking one of the bigger disputes in the history of science. Read The [...]

Novartis to Pay $390M Over Pharmacy Kickbacks

Novartis Pharmaceuticals Corp is settling on charges in the US that it paid specialty pharmacies illegal kickbacks in exchange for inducing patients to refill certain medications to the price of $390 Million. See more details here. (Source: Betty Palmer, Daily Star Albany, 11/21/15)[...]

Does Citizenship Require Taking Responsibility for Each Other?

Yes! Citizenship does require taking some responsibility for one another, and as a nation, the US has decided that The Patient Protection and Affordable Care Act is here to stay, so can Republicans stop fighting it and help to shape it? See more here. (Source: First Report Managed Care, 11/24/15)[...]

ICER Releases Final Report on PCSK9 Use

The Institute for Clinical and Economic Review (ICER) recently posted the final report PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks, along with its accompanying Action Guides to the New England Comparative Effectiveness Public Advisory Co[...]

US Forum Addresses Drug Pricing, Innovation, Access and Affordability

A recent Health and Human Services forum on prescription drug prices brought all players to the table to discuss innovation, patient access and affordability. The forum included patients, patient advocates, Pharmaceutical and Insurance Executives, Government officials and more. Were they able to fin[...]

Obama Health Chief Speaks Out Against High Drug Prices

United States Secretary of Health and Human Services Sylvia Mathews Burwell recently spoke out against high drug prices during an administration forum on the topic. See what she had to say here. (Source: Peter Sullivan, The Hill, 11/20/15)[...]

Infographic: Compliance Rates for US Childhood Vaccinations

Researchers at RTI Health Solutions, a business unit of RTI International, have recently completed a new study showing approximately 34% of children in the US have not completed all doses of vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) by 24 months of age. Infograp[...]

Harvard Pilgrim/Amgen Exclusive Deal on Repatha

Harvard Pilgrim recently announced an exclusive deal with Amgen Inc for a Pay-for-Performance deal on Repatha, Amgen's new cholesterol-lowering drug. Find out more about this deal here. (Source: Angela Maas, AISHealth, November 2015)[...]

2 Radical Fixes to Exorbitant Drug Pricing

The September/October 2015 explores some radical solutions to the drug pricing problem in the United States. How would you feel about taking a medication that had not been FDA approved? Read more here. (Source: Journal of Clinical Pathways, 10/27/15)[...]

ICER Report to Review Approaches to Palliative Care

The Institute for Clinical and Economic Review recently announced it will produce a report looking at the comparative effectiveness and value of palliative care delivered outside of the hospital setting. The report will be the subject of the New England Comparative Effectiveness Public Advisory Coun[...]

Obama Forum Discusses Pharmaceutical Pricing

The Obama administration held a forum Friday to discuss access to specialty and other expensive drugs, seeking input from providers, insurers, employers, drugmakers and consumer advocates. "Medical innovation is meaningless if nobody can afford it," said AARP Chief Public Policy Officer Debra Whitma[...]

Call for Abstracts – ISPOR 21st Annual International Meeting

The ISPOR 21st Annual International Meeting is the place to share your new research as a podium or poster presentation, interact with attendees during a workshop on your innovative experiences in outcomes research, or debate your views on a controversial topic in an issue panel session. Submit your [...]

AFPE Call for Applications Now Open

The American Foundation for Pharmaceutical Education's call for applications is now open. Find out more about the fellowship programs and deadlines here. (Source: AFPE, 2015)[...]

Key Findings Of the Global Medicines Use in 2020 Report

Get the results of the Global Medicines Use in 2020: Outlook and Implications report here. (Source: The New York Times, 11/18/15)[...]

AMCP Poster Abstract Submission Site Now Open

The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting recently opened their poster abstract submission site. Find out more here. (Source: AMCP, 2015)[...]

Recap Of the NAMCP Fall Managed Care Forum

Did you miss the National Association of Managed Care Physicians (NAMCP) Fall Managed Care Forum? Get a quick recap of what you missed here. (Source: First Report Managed Care)[...]

Can the U.S. Find a Cure for Financial Toxicity?

The Financial impact of Cancer Drugs is increasing around the globe, and patients, physicians, payers and government concerns continue to grow in the United States. Find out more about new reimbursement methodologies here. (Source: Gary Owens, Journal of Clinical Pathways, September/October 2015)[...]

How Industry Is Trying to Fight Drug Prices

Outcomes-based agreements are contracts that link payments to drug makers to how well the drug performs. Why it's attractive: It's a popular strategy offered up by the drug industry and has cautious support from payers. The competing industries are in rare agreement because of the realization that t[...]

Who are the Big Players Measuring Prescription Drug Value?

Escalating drug prices in the United States have spawned multiple private-sector initiatives designed to help physicians, payers, and patients understand the value of new therapies. Learn about the most prominent players developing initiatives and their missions here. (Source: Peter Neumann, The Ne[...]

Which Drugs Will the ICER Review in 2016?

The Institute for Clinical and Economic Review (ICER) recently released an initial list of drugs it plans to review in 2016. Find out more about the ICER's new drug assessment program, which drugs will be reviewed, and how they were chosen, here. (Source: Mitchell Stein, ICER, 11/19/15)[...]

Kadcyla Price Too High for NICE Recommendation

The National Institute for Health and Care Excellence (NICE) recently published final draft guidance on Roche's breast cancer combination treatment, Kadcyla, deciding not to recommend Kadcyla for treatment on the basic of cost. Read more here. (Source: NICE, 11/17/15)[...]

Are the Majority Of Published Research Findings Truly False?

Among increasing concern with the accuracy of published research findings, could one prove that most claimed research findings are false? Find out more here. (Source: John Loannidis, PLoS Medicine, August 2005)[...]

Washington Targets Drug Prices – Will Payers Or Pharma Be to Blame?

With Republicans joining the Democrat's call for action, pharma and payers begin pointing their fingers at each other. Who is to blame? Pharma, Payers, maybe both? Read more here. (Source: Tracy Staton, FiercePharma, 11/16/15)[...]

Doctors Vote for Ban on Drug Ads

The American Medical Association (AMA) recently approved a new policy supporting a ban on direct-to-consumer advertising for prescription drugs and implantable medical devices. Read more here. (Source: Deirdre Fulton, CommonDreams, 11/17/15)[...]

Who Has AMCP Appointed As New Executive Director?

The Academy of Managed Care Pharmacy (AMCP) recently announced the appointment of a new Executive Director of the AMCP Foundation. Join us in welcoming Paula J. Eichenbrenner in her new position at AMCP. Find out more here. (Source: AMCP, 11/17/15)[...]

Download: Advancing Evidence Based Decision Making Toolkit

Listed as one of Evidence Soup's 5 Links of the week, this report describes in detail how researchers, policymakers, and program administrators can recognize opportunities for experiments and carry them out. Specifically, the report focuses on opportunistic experiments, defined as randomized control[...]

Can Experimental Studies Be More Like the Real World?

Clinical trials are great to prove effectiveness or safety, but what happens when real people in the real world are prescribed this medication? Does age make a difference? How about Comorbidities? Ultimately, we want to know what happens when the drug is used in routine clinical practice. The answer[...]


Stay Connected